Amgen and Merck kick off a combo cancer trial

Amgen ($AMGN) and Merck ($MRK) have launched an early-stage trial pairing their respective cancer immunotherapies, looking to confirm the clinical and commercial promise of combination approaches to cancer. The two companies have dosed their first subject in a planned 110-patient trial, administering Amgen's cancer vaccine T-Vec alongside Merck's PD-1-blocking pembrolizumab, approved as Keytruda, to see how well the cocktail can treat melanoma. More

Suggested Articles

The deal gives J&J a stake in the development and commercialization of anticoagulants including phase 2-ready secondary stroke candidate BMS-986177.

Boehringer gained the global rights to OSE's SIRP-alpha antagonist, which is in development for solid tumors.

Lilly is diving into encapsulated beta cell treatments, designed to restore insulin production in patients with Type 1 diabetes.